Mechanistically, the effects of celecoxib appear to be COX2-independent through AMP-dependent kinase regulation of mTOR and β-catenin, two important mediators of TKI resistance in CML stem cells. Here, MTOR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.